# EDGAR Filing Document

**Accession Number:** 0001090872
**File Stem:** 0001193125-25-251622
**Filing Date:** 2025-10
**Character Count:** 13216
**Document Hash:** f5e557b7d9342eeabf429d53ca57d13d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-251622.hdr.sgml**: 20251027

**ACCESSION NUMBER**: 0001193125-25-251622

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20251023

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**FILED AS OF DATE**: 20251027

**DATE AS OF CHANGE**: 20251027

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AGILENT TECHNOLOGIES, INC.
- **CENTRAL INDEX KEY:** 0001090872
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 770518772
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1031

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15405
- **FILM NUMBER:** 251420138

**BUSINESS ADDRESS:**
- **STREET 1:** 5301 STEVENS CREEK BLVD
- **CITY:** SANTA CLARA
- **STATE:** CA
- **ZIP:** 95051
- **BUSINESS PHONE:** (408) 345-8886

**MAIL ADDRESS:**
- **STREET 1:** 5301 STEVENS CREEK BLVD, MS 1A-LC
- **STREET 2:** P.O. BOX 58059
- **CITY:** SANTA CLARA
- **STATE:** CA
- **ZIP:** 95052-8059

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AGILENT TECHNOLOGIES INC
- **DATE OF NAME CHANGE:** 19990816

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HP MEASUREMENT INC
- **DATE OF NAME CHANGE:** 19990716

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** October 23, 2025<br>

------

AGILENT TECHNOLOGIES, INC.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-15405 | 77-0518772 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 5301 Stevens Creek Boulevard |  |  |
| Santa Clara**,** California |  | 95051 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** 800 227-9770<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | |
|:---|:---|
| **<br>Title of each class** | **<br>Name of each exchange on which registered** |
| Common Stock, $0.01 par value<br> A | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(c) On October 23, 2025, Agilent Technologies, Inc. (the "Company") appointed Adam S. Elinoff as Senior Vice President and Chief Financial Officer ("CFO") and principal financial officer of the Company effective November 17, 2025 (the "Start Date"), replacing Rodney Gonsalves, who has served as the Company's Interim CFO and Interim Principal Financial Officer since July 31, 2025. Mr. Gonsalves will continue to serve as the Company's Vice President, Corporate Controller and Principal Accounting Officer.

Mr. Elinoff, age 48, has served as Vice President, Investor Relations and Treasurer of Amgen Inc. ("Amgen"), a global biotechnology company, since July 2025. Mr. Elinoff joined Amgen in 2006 and has held a series of finance, strategy, and transformation roles of increasing responsibility. From 2023 to July 2025, Mr. Elinoff served as Vice President, Finance and Treasurer. From 2020 to 2023, he served as Regional Chief Financial Officer for Europe, Middle East, Africa, Latin America, and Canada. From 2017 to 2020, he served as Executive Director and Head of Corporate Financial Planning and Analysis. Mr. Elinoff holds a Master of Business Administration from the W. P. Carey School of Business at Arizona State University and a Bachelor of Arts degree in Economics from Hamilton College.

There are no arrangements or understandings between Mr. Elinoff and any other persons pursuant to which Mr. Elinoff was appointed Senior Vice President and CFO. Mr. Elinoff does not have any family relationship with any of the Company's directors or executive officers or any persons nominated or chosen by the Company to be a director or executive officer. Mr. Elinoff has no direct or indirect material interest in any transaction or proposed transaction required to be reported under Item 404(a) of Regulation S-K.

(e) In connection with Mr. Elinoff's employment, the Compensation Committee of the Company (the "Committee") approved the following compensation package: (i) effective as of the Start Date (a) a base salary of $700,000, and (b) eligibility to participate in the Company's short-term annual incentive (bonus) program equal to 80% of his base salary; and (ii) effective as of November 18, 2025, a grant of (a) restricted stock units ("RSUs") of the Company's common stock for fiscal 2025 in the target amount of $1,100,000 and (b) performance-based restricted stock units of the Company's common stock for the fiscal 2026 to fiscal 2028 performance period in the target amount of $1,650,000 (collectively, the "FY 2026 Awards").

In addition, the Committee approved (i) a one-time cash bonus of $800,000, subject to repayment if Mr. Elinoff terminates his employment for any reason within twelve months, and (ii) a one-time sign-on grant of (a) RSUs of the Company's common stock in the target amount of $560,000, and (b) performance-based restricted stock units of the Company's common stock for the fiscal 2026 to fiscal 2028 performance period in the target amount of $840,000 (collectively, the "Sign-On Awards", and, together with the FY 2026 Awards, the "Awards").

The Awards are subject to the standard terms and conditions of the Company's forms of equity award agreements under Agilent's 2018 Stock Plan. The RSUs have a four-year vesting schedule. The performance-based restricted stock unit award will vest on October 31, 2028 with the actual payout ranging between 0% and 200% of the target based on the Company's actual performance against performance goals established by the Committee for the three-year period ending on October 31, 2028. Mr. Elinoff will also enter into a change of control agreement with the Company in the form which is filed as Exhibit 10.37 to the Company's Annual Report on Form 10-K filed with the SEC on December 22, 2014 and is incorporated by reference herein.

## Item 7.01 Regulation FD Disclosure.
The Company issued a press release on October 27, 2025 announcing the appointment of Mr. Elinoff as the Company's CFO. A copy of the press release is furnished as Exhibit 99.1 to this report.

The information in this Item 7.01 and Exhibit 99.1, attached hereto, are intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or

------

otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

## Item 9.01 Financial Statements and Exhibits.
(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [<u>99.1</u>](a-ex99_1.htm) | Press release dated October 27, 2025, announcing new Chief Financial Officer  |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | **AGILENT TECHNOLOGIES, INC.** |
| Date: | October 27, 2025 | By:  | /s/ P. Diana Chiu |
|  |  | Name:  | P. Diana Chiu |
|  |  | Title: | Vice President, Assistant General Counsel<br>& Assistant Secretary |

---

------

## Exhibit 99.1

Exhibit 99.1

**Agilent Names Adam S. Elinoff as Chief Financial Officer**

*SANTA CLARA, Calif., Oct. 27, 2025 –* Agilent Technologies Inc. (NYSE: A) today announced the appointment of Adam S. Elinoff as chief financial officer, effective Nov. 17.

Elinoff brings two decades of financial experience spanning corporate finance, investor relations, strategy and business transformation, and has a proven record of driving enterprise-wide transformations, optimizing financial operations and scaling global capabilities.

He joins Agilent from Amgen, a worldwide pioneer in biotechnology, where he advanced through a series of finance, strategy and transformation leadership roles over a total of 19 years, most recently serving as vice president of finance and treasurer.

"We are thrilled to welcome Adam to the Agilent team and look forward to partnering with him as we build on our momentum and execute our financial priorities," said Padraig McDonnell, Agilent president and CEO. "Adam's expertise in strategic planning and M&A and his commitment to cross-functional collaboration will be invaluable as we accelerate Agilent's Ignite Operating System. We are confident his industry experience and leadership will help us deliver even greater innovation and value creation for our customers and shareholders."

"On behalf of the Agilent Board and management team, I would also like to thank Rodney Gonsalves for his leadership and service as interim chief financial officer," he said. "Rodney will continue in his role as corporate controller and principal accounting officer."

"Agilent is a global leader and powerhouse of innovation in life sciences, diagnostics, and applied markets, and it is a privilege to join as the company's next CFO — especially at this exciting time for the company," Elinoff said. "I'm eager to hit the ground running, working closely with Padraig and the rest of the executive team as we build on Agilent's strong foundation and help accelerate the company's next chapter of success."

In addition to his recent finance roles at Amgen, Elinoff previously served as regional CFO for Europe, the Middle East, Africa, Latin America, and Canada for Amgen in Switzerland, overseeing finance and analytics teams across 67 markets and managing a $6 billion P&L. During his tenure, he delivered significant revenue and profitability growth, streamlined regional operations, and established the Amgen Capability Center in Portugal. Elinoff's career at Amgen also includes leadership roles in corporate financial planning and analysis, global business services, corporate strategy, and R&D finance.

------

Before joining Amgen, Elinoff held finance-leadership positions at Shire Pharmaceuticals and International Rectifier. He began his career as a small-enterprise-development volunteer with the Peace Corps in Senegal, where he established microcredit programs for entrepreneurs in underserved regions.

Elinoff holds a Bachelor of Arts in Economics from Hamilton College and an MBA from Arizona State University's W. P. Carey School of Business.

***About Agilent Technologies***

*Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.51 billion in fiscal year 2024 and employs approximately 18,000 people worldwide. Information about Agilent is available at* www.agilent.com*. To receive the latest Agilent news, subscribe to our* Newsroom*. Follow Agilent on* LinkedIn *and* Facebook*.*

***Contacts***

**INVESTOR CONTACT:**

Tejas Savant

+1 917-574-4018

tejas.savant@agilent.com

**MEDIA CONTACT:** 

Kate Coyle

+1 302-633-7490

kate.coyle@agilent.com

###

------